Market revenue in 2022 | USD 70.0 million |
Market revenue in 2030 | USD 149.1 million |
Growth rate | 9.9% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 52.29% in 2022. Horizon Databook has segmented the Australia non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
In Australia, TGA regulates the pricing and reimbursement of IVD products under the Therapeutics Goods Act 1989 and its delegated legislation. The TGA is responsible for assessing, evaluating, and monitoring medicines manufactured and supplied in Australia.
The Australian government launched the Pharmaceutical Benefits Scheme under the National Health Act 1953 to provide different products at subsidized and free of cost to patients. Australia has a codependent submission process to evaluate the medicine and the companion diagnostic products.
For instance, the Medical Services Advisory Committee and Pharmaceutical Benefits Advisory Committee assess individual and combined evidence. Both committees must provide a favorable recommendation for the test to be included on the Medicare Benefits Schedule (MBS) and the medication on the Pharmaceutical Benefits Scheme.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into Australia non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account